Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 31Observational 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1

Conditions

Neoplasms 2Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Surveys and Questionnaires 529Blood Specimen Collection 405Surgical Procedures, Operative 151Interviews as Topic 131Radiotherapy 130Observation 122Drug Therapy 122Magnetic Resonance Spectroscopy 104Biopsy 103Specimen Handling 70Data Collection 70Neoadjuvant Therapy 65Immunohistochemistry 64Magnetic Resonance Imaging 61Immune Checkpoint Inhibitors 58Watchful Waiting 51Immunotherapy 51Bevacizumab 49Positron Emission Tomography Computed Tomography 46Ultrasonography 44Liquid Biopsy 41Hematologic Tests 41Tomography, X-Ray Computed 40Therapeutics 40Radiosurgery 40Colonoscopy 40pembrolizumab 37Hepatectomy 37Gene Expression Profiling 36High-Energy Shock Waves 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Observational × rucaparib × Clear all
NCT04539327 2026-03-18

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

Grupo Español de Investigación en Cáncer de Ovario

Completed
51 enrolled 28 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Completed
2,336 enrolled
Tumor-Agnostic

Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

University Hospital, Caen

Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡